top of page
SCR101 topical skin product
Active ingredient
Small molecule compound which has been safe in human for more than 30 years
Target indication
Acne
Skin redness, including hypertrophic scar
QOL of post-surgical operation
Significant market size
MOA
Inhibition of neovascularization
Delivery to skin tissue
Efficient and rapid delivery
Current therapy
Acne: Clindamycin gel. SCR101 is differentiated from clindamycin gel.
Hypertrophic scar: No FDA approved drug
Patents
A US patent of SCR101 skin products has been issued in July, 2020.
bottom of page